Biotechnology

Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...

2021-11-12 07:55 2854

Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections

SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...

2021-11-12 02:00 1620

Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting

-  Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be  demonstrated during the event in booth #423 -  One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...

2021-11-11 23:00 1381

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry andin-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small mo...

2021-11-11 21:33 2169

Happiness Biotech Group Limited Announces Name Change to Happiness Development Group Limited and Re-Designation of Its Ordinary Shares

NANPING, China, Nov. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (" Happiness" or the "Company"), (NASDAQ: HAPP), is pleased to announce that effective onNovember 12, 2021, the Company will change its name to "Happiness Development Group Limited" (the "Name Change"). In addition, the ...

2021-11-11 21:00 1267

New EZZ genomic products attract strong Chinese interest at CIIE 2021

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- From November 5 to 10, the 4th China International ImportExpo took place in Shanghai, with a focus on global high-tech companies. EZZ Life Science Holdings Limited (ASX: EZZ), a leading company in life sciences inAustralia, was invited to participate for the ...

2021-11-11 04:00 2106

Hill's Pet Nutrition Partners With Bond Pet Foods, Inc. To Develop A Craft Meat Protein Produced Through Precision Fermentation

New Agreement to Explore Sustainable Meat Protein to Provide Long-Term Options for Cat and Dog Nutrition TOPEKA, Kan. and BOULDER, Colo., Nov. 10, 2021 /PRNewswire/ -- Hill's Pet Nutrition, a global leader in biology-based pet nutrition, and Bond Pet Foods, Inc., the Boulder-based leader in crea...

2021-11-10 22:00 1797

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a ...

2021-11-10 17:00 1386

Say Cheese: Sophie's BioNutrients co-creates with Ingredion to develop its first microalgae-based dairy-free cheese

SINGAPORE, Nov. 10, 2021 /PRNewswire/ -- Sophie's BioNutrients , a next-generation sustainable urban food production technology company, together withIngredion Idea Labs ® i...

2021-11-10 10:00 2231

One BioMed launches the cartridge-based Xceler8(TM) Nucleic Acid Extraction Platform, the next generation in workflow simplification

SINGAPORE, Nov. 10, 2021 /PRNewswire/ -- One BioMed, a company focused on advancing human health through innovation, announced today the launch of their Xceler8™ Platform for high-yield extraction and purification of nucleic acids from biological samples. Pre-filled with all the necessary reagent...

2021-11-10 08:00 1459

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC

* Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity * Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab ...

2021-11-09 21:05 1489

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-a...

2021-11-09 21:00 1995

Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of theApril...

2021-11-09 20:55 1948

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...

2021-11-09 20:30 1305

Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible

SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...

2021-11-09 18:05 1391

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-11-09 16:30 2420

InnoRNA of China participates in the Hanmi Science Consortium …"To join forces to eliminate 'vaccine divide'"

SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Global businesses and institutes are knocking on the door to the Hanmi Science Consortium having proprietary LNP technology. After Hanmi Science concluded a 'pandemic science alliance agreement' with theUniversity of Oxford, increasingly more entit...

2021-11-09 14:20 1358

InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH

BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting onDecember 11-14, 2021, which will be hold o...

2021-11-09 13:06 1676

Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery

SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...

2021-11-09 10:47 1913

BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration.  BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...

2021-11-08 22:59 2659
1 ... 182183184185186187188 ... 288